Hemophilia B - Global Strategic Business Report

The global market for Hemophilia B was estimated at US$4.1 Billion in 2024 and is projected to reach US$6.4 Billion by 2030, growing at a CAGR of 7.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Hemophilia B market.

Global Hemophilia B Market - Key Trends and Drivers Summarized

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a protein essential for blood clotting. This condition primarily affects males due to its X-linked recessive inheritance pattern, with females typically being carriers. Hemophilia B can vary in severity, with symptoms ranging from mild to severe bleeding episodes, often triggered by injuries or surgeries. Spontaneous bleeding into joints and muscles is a common complication, leading to pain, swelling, and long-term joint damage if not properly managed. The diagnosis is confirmed through blood tests that measure factor IX activity, and genetic testing can identify carriers and inform family planning decisions. Treatment usually involves regular infusions of recombinant or plasma-derived factor IX concentrates to prevent and control bleeding episodes, greatly improving the quality of life for those affected.

Advancements in medical research have significantly improved the management and understanding of Hemophilia B. Gene therapy has emerged as a promising treatment option, aiming to provide a one-time cure by delivering functional copies of the factor IX gene to the liver, where it can produce the necessary clotting factor. Early clinical trials have shown encouraging results, with patients achieving sustained levels of factor IX activity and a substantial reduction in bleeding episodes. Additionally, extended half-life factor IX products, which require less frequent dosing, have been developed, offering greater convenience and adherence to treatment regimens. These innovations, along with enhanced diagnostic techniques and comprehensive care programs, are transforming the landscape of Hemophilia B management, enabling individuals to lead more active and fulfilling lives.

The growth in the Hemophilia B treatment market is driven by several factors. Technological advancements, such as gene therapy and extended half-life clotting factor products, are providing more effective and convenient treatment options. The increasing prevalence of Hemophilia B, coupled with greater awareness and diagnosis rates, is expanding the patient pool seeking treatment. Improved healthcare infrastructure and access to specialized care in emerging economies are also contributing to market growth. Furthermore, patient advocacy groups and educational initiatives are playing a crucial role in promoting early diagnosis and treatment adherence. The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is another key driver, enhancing the efficacy and safety of therapies. As pharmaceutical companies invest in research and development, the pipeline of novel therapies continues to grow, promising further advancements in the management of Hemophilia B.

SCOPE OF STUDY:

The report analyzes the Hemophilia B market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Disease Severity (Moderate Disease, Mild Disease, Severe Disease); Treatment (On-Demand Therapy, Prophylaxis, Inhibitors)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Moderate Disease segment, which is expected to reach US$2.7 Billion by 2030 with a CAGR of a 7.5%. The Mild Disease segment is also set to grow at 8.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.1 Billion in 2024, and China, forecasted to grow at an impressive 7.5% CAGR to reach $1.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Hemophilia B Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hemophilia B Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Hemophilia B Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Bayer AG, Be Biopharma, Inc., Centessa Pharmaceuticals Plc, CSL, Freeline Therapeutics and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 53 companies featured in this Hemophilia B market report include:

• Bayer AG
• Be Biopharma, Inc.
• Centessa Pharmaceuticals Plc
• CSL
• Freeline Therapeutics
• Grifols USA, LLC
• Intellia Therapeutics, Inc.
• LFB Biotechnologies
• Medexus Pharma, Inc. (IXINITY)
• novoMEDLINK
• Pfizer, Inc.
• Spark Therapeutics, Inc.
• Swedish Orphan Biovitrum AB (Sobi)
• Takeda Pharmaceutical Company
• uniQure N.V.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.